{"PubmedArticle":{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM","IndexingMethod":"Automated"},"PMID":{"@attributes":{"Version":"1"},"@text":"41979449"},"DateCompleted":{"Year":"2026","Month":"04","Day":"14"},"DateRevised":{"Year":"2026","Month":"04","Day":"14"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":{"@attributes":{"IssnType":"Print"},"@text":"1118-4841"},"JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"30","Issue":"7","PubDate":{"Year":"2026","Month":"Apr","Day":"14"}},"Title":"African journal of reproductive health","ISOAbbreviation":"Afr J Reprod Health"},"ArticleTitle":"The therapeutic potential of exosomes derived from mesenchymal stem cells for premature ovarian failure: A systematic.","Pagination":{"StartPage":"124","EndPage":"138","MedlinePgn":"124-138"},"ELocationID":[{"@attributes":{"EIdType":"doi","ValidYN":"Y"},"@text":"10.29063\/ajrh2026\/v30i7.11"},{"@attributes":{"EIdType":"pii","ValidYN":"Y"},"@text":"(Afr J Reprod Health 2026; 30 [7]:124-138"}],"Abstract":{"AbstractText":["This review evaluates mesenchymal stem cell-derived exosomes (MSC-Exos) for treating premature ovarian failure (POF). A comprehensive search was conducted across five databases, including PubMed, Embase, and Web of Science (WoS), yielding 17 English-language studies published between 2016 and 2025. Studies primarily using animal and in vitro models assessed the therapeutic effects and mechanisms of MSC-Exos from diverse sources. MSC-Exos significantly elevated estrogen levels, reduced follicle-stimulating hormone (FSH), increased antral follicle counts, and restored estrous cyclicity. Specifically, BMSC-Exos activated the PI3K\/AKT pathway via miRNAs to suppress granulosa cell apoptosis; hUCMSC-Exos mitigated cellular senescence and autophagy; ADSC-Exos promoted follicular development through SMAD and SIRT1\/FOXO1; PMSC-Exos attenuated ROS damage by improving mitochondrial function; AFSC-Exos together with MenSC-Exos enhanced oocyte maturation via the P53 pathway. Notably, perinatal exosomes showed 18-32% greater efficacy in functional recovery than adult-tissue counterparts with fewer doses. MSC-Exos present a promising therapeutic strategy for POF by targeting apoptosis, autophagy, angiogenesis, and oxidative stress. Perinatal-derived exosomes offer superior potential due to their non-invasive collection and minimal ethical concerns. Nonetheless, challenges pertaining to heterogeneity, long-term safety, and standardized manufacturing necessitate resolution through multicenter clinical trials to advance clinical applicability.."],"CopyrightInformation":"African Journal of Reproductive Health \u00a9 2026."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Chen","ForeName":"Chu-Qiao","Initials":"CQ","AffiliationInfo":[{"Affiliation":"Department of Gyn ecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China."},{"Affiliation":"Department of Gynecology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Wang","ForeName":"Xin-Run","Initials":"XR","AffiliationInfo":[{"Affiliation":"Department of Gyn ecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Zhao","ForeName":"Xiao-Jing","Initials":"XJ","AffiliationInfo":[{"Affiliation":"Department of Gyn ecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Wang","ForeName":"Liang","Initials":"L","AffiliationInfo":[{"Affiliation":"Department of Gyn ecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China."}]}]},"Language":["eng"],"PublicationTypeList":{"PublicationType":[{"@attributes":{"UI":"D016428"},"@text":"Journal Article"},{"@attributes":{"UI":"D000078182"},"@text":"Systematic Review"}]}},"MedlineJournalInfo":{"Country":"Nigeria","MedlineTA":"Afr J Reprod Health","NlmUniqueID":"9712263","ISSNLinking":"1118-4841"},"CitationSubset":["IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":{"@attributes":{"UI":"D016649","MajorTopicYN":"Y"},"@text":"Primary Ovarian Insufficiency"},"QualifierName":[{"@attributes":{"UI":"Q000628","MajorTopicYN":"N"},"@text":"therapy"}]},{"DescriptorName":{"@attributes":{"UI":"D005260","MajorTopicYN":"N"},"@text":"Female"}},{"DescriptorName":{"@attributes":{"UI":"D006801","MajorTopicYN":"N"},"@text":"Humans"}},{"DescriptorName":{"@attributes":{"UI":"D055354","MajorTopicYN":"Y"},"@text":"Exosomes"},"QualifierName":[{"@attributes":{"UI":"Q000637","MajorTopicYN":"N"},"@text":"transplantation"},{"@attributes":{"UI":"Q000378","MajorTopicYN":"N"},"@text":"metabolism"}]},{"DescriptorName":{"@attributes":{"UI":"D059630","MajorTopicYN":"Y"},"@text":"Mesenchymal Stem Cells"},"QualifierName":[{"@attributes":{"UI":"Q000166","MajorTopicYN":"N"},"@text":"cytology"},{"@attributes":{"UI":"Q000378","MajorTopicYN":"N"},"@text":"metabolism"}]},{"DescriptorName":{"@attributes":{"UI":"D000818","MajorTopicYN":"N"},"@text":"Animals"}},{"DescriptorName":{"@attributes":{"UI":"D017209","MajorTopicYN":"N"},"@text":"Apoptosis"}},{"DescriptorName":{"@attributes":{"UI":"D045164","MajorTopicYN":"Y"},"@text":"Mesenchymal Stem Cell Transplantation"},"QualifierName":[{"@attributes":{"UI":"Q000379","MajorTopicYN":"N"},"@text":"methods"}]}]},"OtherAbstract":[{"@attributes":{"Type":"Publisher","Language":"fre"},"AbstractText":["Cette revue \u00e9value l\u2019utilisation d\u2019exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses (MSC-Exos) pour le traitement de l\u2019insuffisance ovarienne pr\u00e9matur\u00e9e (IOP). Une recherche exhaustive a \u00e9t\u00e9 men\u00e9e dans cinq bases de donn\u00e9es, notamment PubMed, Embase et Web of Science (WoS), et a permis d\u2019identifier 17 \u00e9tudes publi\u00e9es en anglais entre 2016 et 2025. Les \u00e9tudes, reposant principalement sur des mod\u00e8les animaux et in vitro, ont examin\u00e9 les effets th\u00e9rapeutiques et les m\u00e9canismes d\u2019action des MSC-Exos issus de diff\u00e9rentes sources. Les MSC-Exos ont significativement augment\u00e9 les taux d\u2019\u0153strog\u00e8nes, r\u00e9duit l\u2019hormone folliculostimulante (FSH), accru le nombre de follicules antraux et r\u00e9tabli la cyclicit\u00e9 \u0153strale. Plus pr\u00e9cis\u00e9ment, les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses de la moelle osseuse (BMSC-Exos) ont activ\u00e9 la voie PI3K\/AKT via des miARN afin de supprimer l\u2019apoptose des cellules de la granulosa ; les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses du cordon ombilical humain (hUCMSC-Exos) ont att\u00e9nu\u00e9 la s\u00e9nescence cellulaire et modul\u00e9 l\u2019autophagie ; les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses du tissu adipeux (ADSC-Exos) ont favoris\u00e9 le d\u00e9veloppement folliculaire via les voies SMAD et SIRT1\/FOXO1 ; les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses placentaires (PMSC-Exos) ont r\u00e9duit les dommages li\u00e9s aux esp\u00e8ces r\u00e9actives de l\u2019oxyg\u00e8ne (ROS) en am\u00e9liorant la fonction mitochondriale ; les exosomes d\u00e9riv\u00e9s de cellules souches du liquide amniotique (AFSC-Exos), associ\u00e9s aux exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses menstruelles (MenSC-Exos), ont am\u00e9lior\u00e9 la maturation ovocytaire via la voie P53. Il est \u00e0 noter que les exosomes d\u2019origine p\u00e9rinatale ont montr\u00e9 une efficacit\u00e9 de r\u00e9cup\u00e9ration fonctionnelle sup\u00e9rieure de 18 \u00e0 32 % \u00e0 celle des exosomes issus de tissus adultes, et ce avec un nombre de doses plus faible. Les MSC-Exos constituent une strat\u00e9gie th\u00e9rapeutique prometteuse pour l\u2019IOP en ciblant l\u2019apoptose, l\u2019autophagie, l\u2019angiogen\u00e8se et le stress oxydatif. Les exosomes d\u2019origine p\u00e9rinatale offrent un potentiel sup\u00e9rieur gr\u00e2ce \u00e0 un pr\u00e9l\u00e8vement non invasif et \u00e0 des pr\u00e9occupations \u00e9thiques limit\u00e9es. N\u00e9anmoins, des d\u00e9fis li\u00e9s \u00e0 l\u2019h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9, \u00e0 la s\u00e9curit\u00e9 \u00e0 long terme et \u00e0 la standardisation de la fabrication doivent \u00eatre r\u00e9solus au moyen d\u2019essais cliniques multicentriques afin de favoriser une application clinique."],"CopyrightInformation":"African Journal of Reproductive Health \u00a9 2026."},{"@attributes":{"Type":"Publisher","Language":"fre"},"AbstractText":["Cette revue \u00e9value l\u2019utilisation d\u2019exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses (MSC-Exos) pour le traitement de l\u2019insuffisance ovarienne pr\u00e9matur\u00e9e (IOP). Une recherche exhaustive a \u00e9t\u00e9 men\u00e9e dans cinq bases de donn\u00e9es, notamment PubMed, Embase et Web of Science (WoS), et a permis d\u2019identifier 17 \u00e9tudes publi\u00e9es en anglais entre 2016 et 2025. Les \u00e9tudes, reposant principalement sur des mod\u00e8les animaux et in vitro, ont examin\u00e9 les effets th\u00e9rapeutiques et les m\u00e9canismes d\u2019action des MSC-Exos issus de diff\u00e9rentes sources. Les MSC-Exos ont significativement augment\u00e9 les taux d\u2019\u0153strog\u00e8nes, r\u00e9duit l\u2019hormone folliculostimulante (FSH), accru le nombre de follicules antraux et r\u00e9tabli la cyclicit\u00e9 \u0153strale. Plus pr\u00e9cis\u00e9ment, les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses de la moelle osseuse (BMSC-Exos) ont activ\u00e9 la voie PI3K\/AKT via des miARN afin de supprimer l\u2019apoptose des cellules de la granulosa ; les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses du cordon ombilical humain (hUCMSC-Exos) ont att\u00e9nu\u00e9 la s\u00e9nescence cellulaire et modul\u00e9 l\u2019autophagie ; les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses du tissu adipeux (ADSC-Exos) ont favoris\u00e9 le d\u00e9veloppement folliculaire via les voies SMAD et SIRT1\/FOXO1 ; les exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses placentaires (PMSC-Exos) ont r\u00e9duit les dommages li\u00e9s aux esp\u00e8ces r\u00e9actives de l\u2019oxyg\u00e8ne (ROS) en am\u00e9liorant la fonction mitochondriale ; les exosomes d\u00e9riv\u00e9s de cellules souches du liquide amniotique (AFSC-Exos), associ\u00e9s aux exosomes d\u00e9riv\u00e9s de cellules souches m\u00e9senchymateuses menstruelles (MenSC-Exos), ont am\u00e9lior\u00e9 la maturation ovocytaire via la voie P53. Il est \u00e0 noter que les exosomes d\u2019origine p\u00e9rinatale ont montr\u00e9 une efficacit\u00e9 de r\u00e9cup\u00e9ration fonctionnelle sup\u00e9rieure de 18 \u00e0 32 % \u00e0 celle des exosomes issus de tissus adultes, et ce avec un nombre de doses plus faible. Les MSC-Exos constituent une strat\u00e9gie th\u00e9rapeutique prometteuse pour l\u2019IOP en ciblant l\u2019apoptose, l\u2019autophagie, l\u2019angiogen\u00e8se et le stress oxydatif. Les exosomes d\u2019origine p\u00e9rinatale offrent un potentiel sup\u00e9rieur gr\u00e2ce \u00e0 un pr\u00e9l\u00e8vement non invasif et \u00e0 des pr\u00e9occupations \u00e9thiques limit\u00e9es. N\u00e9anmoins, des d\u00e9fis li\u00e9s \u00e0 l\u2019h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9, \u00e0 la s\u00e9curit\u00e9 \u00e0 long terme et \u00e0 la standardisation de la fabrication doivent \u00eatre r\u00e9solus au moyen d\u2019essais cliniques multicentriques afin de favoriser une application clinique."],"CopyrightInformation":"African Journal of Reproductive Health \u00a9 2026."}],"KeywordList":[{"@attributes":{"Owner":"NOTNLM"},"Keyword":[{"@attributes":{"MajorTopicYN":"N"},"@text":"Exosomes"},{"@attributes":{"MajorTopicYN":"N"},"@text":"Mesenchymal stem cells"},{"@attributes":{"MajorTopicYN":"N"},"@text":"Premature ovarian failure"},{"@attributes":{"MajorTopicYN":"N"},"@text":"treatment characteristics"},{"@attributes":{"MajorTopicYN":"N"},"@text":"treatment effect"}]}],"CoiStatement":"The Authors declared no conflict of interest"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"medline"},"Year":"2026","Month":"4","Day":"14","Hour":"12","Minute":"36"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2026","Month":"4","Day":"14","Hour":"12","Minute":"35"},{"@attributes":{"PubStatus":"entrez"},"Year":"2026","Month":"4","Day":"14","Hour":"9","Minute":"53"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"41979449"},{"@attributes":{"IdType":"doi"},"@text":"10.29063\/ajrh2026\/v30i7.11"},{"@attributes":{"IdType":"pii"},"@text":"(Afr J Reprod Health 2026; 30 [7]:124-138"}]}}}}